July 2020 - Page 5 of 5 - BioMedWire (BMW)

ThursdayJul 09, 2020 10:00 am

EU Grants Orphan Medicine Status to Liver Cancer Drug

The European Medicines Agency (“EMA”) recently granted Orphan Medicinal Product designation in the EU to MIV-818 used for the treatment of patients with hepatocellular carcinoma (“HCC”), the primary type of liver cancer. This designation was granted after thorough and careful medical research and guidance about the drug. Orphan Medicinal Product designation gives specific regulatory and financial bonuses to firms to help in developing and marketing therapies that treat chronically debilitating conditions or life-threatening diseases. Studies show that five people in a population of 10,000 individuals are suffering from HCC, a fatal ailment in the European Union. The designation has been…

WednesdayJul 08, 2020 2:00 pm

Spike in Neurological Diseases Fuels Market for Cerebrospinal Fluid Management Products

The world market for cerebrospinal fluid management products is witnessing tremendous growth with rising levels of competition, according to the forecasting done by Transparency Market Research. The major stakeholders in the global market are putting more emphasis on the development of a new product, with further predictions to enhance the competitive environment throughout the forecasting period. Some of these stakeholders are Integra Life Sciences Holding Corporation, Medtronic Plc., DePuy Synthes, B. Braun Melsungen AG, BeckerSmith Medical, Inc., and Spiegelberg GmbH and Co.KG. The mushrooming number of mergers and acquisitions and the increasing investments in research and development activities are predicted…

WednesdayJul 08, 2020 9:30 am

How Can the Diagnosis and Treatment of Rare Diseases Be Improved?

Rare diseases have brought a more significant impact on the lives of several people more than AIDS and cancer combined, and statistics show that more than 450 million people are suffering from rare diseases worldwide. These rare diseases have escalated due to lack of education, shortage of improved technologies and infrastructure, which has made the diagnosis of these diseases so challenging. However, the good news is that steps are being taken to improve the diagnosis and treatment of rare diseases worldwide. The Focus Should Be Changed from North America and Europe to the World For the last 25 years since…

TuesdayJul 07, 2020 3:30 pm

UK Company Secures Funds to Detect Epigenetic Cancer Signs

A University of Oxford spinout focusing on genomics will benefit from a seed round of $11.4 billion. It aims at improving cancer detection by measuring epigenetic changes to tumor DNA circulating in a patient’s blood. The oversubscribed seed funding round was pioneered by Oxford Sciences Innovation. It is a local early-stage investment enterprise connected to the University of Oxford. Base Genomics will make use of technology developed at the University of Oxford called TAPS. TAPS is responsible for detecting epigenetic methylation of DNA at a single-base level. DNA methylation is a method in which cells can switch off specific genes…

TuesdayJul 07, 2020 11:49 am

DarioHealth Corp. (NASDAQ: DRIO) is “One to Watch”

Dario’s popular (4.9 stars on the Apple App Store and 11,000 reviews) chronic condition management platform addresses a $72 billion annual U.S. market opportunity There are roughly 51,000 active users of the Dario platform, including its proprietary medical device, mobile application, and digital and human coaching services Clinical studies show Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension) Patient engagement in therapies leads to health success. The Dario platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario smartphone-connected medical devices…

MondayJul 06, 2020 1:25 pm

Predictive Oncology Inc. (NASDAQ: POAI) Announces Acquisition of Soluble Therapeutics, BioDtech as it Continues Buildout of Precision Medicine Business

Predictive Oncology announced the acquisition of Soluble Therapeutics Inc. & BioDtech Inc. Acquired companies seek to enhance drug development process through the optimization of protein solubility and stability as well as through detection, removal of endotoxins The companies were acquired for consideration amounting to 125,000 common shares and waiving of $1.07 million promissory note issued by parent company, InventaBioTech Predictive Oncology seeks to build out its precision medicine business line, aimed at helping clinicians individualize cancer treatment Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug…

WednesdayJul 01, 2020 12:30 pm

Vivos Therapeutics, Inc. Non-Surgical, Non-Invasive, and Cost-Effective Solution, May Help Relieve OSA-Associated Healthcare Costs

Estimates suggest obstructive sleep apnea (“OSA”) costs the US economy $150 billion annually Medicare beneficiaries with obstructive sleep apnea cost taxpayers $19,566 per year Company’s oral appliances have shown to be effective in over 15,000 patients, successfully treated worldwide by approximately 1,250 trained dentists and doctors It is estimated that obstructive sleep apnea (“OSA”) affects approximately 1 billion people worldwide, of which 54 million are Americans (http://ibn.fm/jBfMi). According to a study published by the Journal of Clinical Sleep Medicine, individuals with untreated OSA face increased health care utilization (“HCU”) and costs across all service aspects. Costs and HCU were evaluated…